Literature DB >> 20165949

[Gastrointestinal stromal tumors of the stomach. Updates and differences compared to other locations].

E Wardelmann1, P Hohenberger, P Reichardt, S Merkelbach-Bruse, H-U Schildhaus, R Büttner.   

Abstract

Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the gastrointestinal tract. Two thirds of them are located in the stomach, another 30% occur in the small bowel, while the remaining tumors occur in the rectum or more rarely in the oesophagus. GIST most commonly grow from the smooth muscular layer towards the serosal surface whereas development towards to the mucosal layer is less frequent. In the latter case ulceration may occur, leading to gastrointestinal bleeding as the main symptom. However, the majority of GIST of the stomach are asymptomatic, resulting in large tumors on initial diagnosis. Most gastric GIST are not visible on endoscopy but may be diagnosed by endosonography. Due to their location in the outer layers of the tubular gastrointestinal tract biopsy is often hindered of even impossible. GIST of the stomach differ from tumors in other locations with regard to their morphology, molecular pathology and prognosis. This present article provides an overview of these differences also with regard to possible therapeutic consequences.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20165949     DOI: 10.1007/s00292-009-1270-9

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  15 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Authors:  Maria Debiec-Rychter; Raf Sciot; Axel Le Cesne; Marcus Schlemmer; Peter Hohenberger; Allan T van Oosterom; Jean-Yves Blay; Serge Leyvraz; Michel Stul; Paolo G Casali; John Zalcberg; Jaap Verweij; Martine Van Glabbeke; Anne Hagemeijer; Ian Judson
Journal:  Eur J Cancer       Date:  2006-04-18       Impact factor: 9.162

Review 3.  Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  P G Casali; L Jost; P Reichardt; M Schlemmer; J-Y Blay
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

4.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.

Authors:  L G Kindblom; H E Remotti; F Aldenborg; J M Meis-Kindblom
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

5.  GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology.

Authors:  Jerzy Lasota; Jerzy Stachura; Markku Miettinen
Journal:  Lab Invest       Date:  2006-01       Impact factor: 5.662

6.  Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations.

Authors:  Abbas Agaimy; Peter H Wünsch; Ferdinand Hofstaedter; Hagen Blaszyk; Petra Rümmele; Andreas Gaumann; Wolfgang Dietmaier; Arndt Hartmann
Journal:  Am J Surg Pathol       Date:  2007-01       Impact factor: 6.394

7.  High incidence of microscopic gastrointestinal stromal tumors in the stomach.

Authors:  Kaori Kawanowa; Yuji Sakuma; Shinji Sakurai; Tsunekazu Hishima; Yoshiaki Iwasaki; Kana Saito; Yoshinori Hosoya; Takashi Nakajima; Nobuaki Funata
Journal:  Hum Pathol       Date:  2006-09-25       Impact factor: 3.466

8.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

9.  PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features.

Authors:  K Pauls; S Merkelbach-Bruse; D Thal; R Büttner; E Wardelmann
Journal:  Histopathology       Date:  2005-02       Impact factor: 5.087

Review 10.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

View more
  5 in total

Review 1.  [Translational research and diagnosis in GIST].

Authors:  E Wardelmann
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 2.  Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting.

Authors:  Abbas Agaimy
Journal:  Int J Clin Exp Pathol       Date:  2010-05-05

3.  Management of early asymptomatic gastrointestinal stromal tumors of the stomach.

Authors:  Hans Scherübl; Siegbert Faiss; Wolfram-Trudo Knoefel; Eva Wardelmann
Journal:  World J Gastrointest Endosc       Date:  2014-07-16

Review 4.  Extra-gastrointestinal stromal tumor arising in the lesser omentum with a platelet-derived growth factor receptor alpha (PDGFRA) mutation: a case report and literature review.

Authors:  Kohei Kanamori; Yukinori Yamagata; Yoshitaka Honma; Keiichi Date; Takeyuki Wada; Tsutomu Hayashi; Sho Otsuki; Shigeki Sekine; Takaki Yoshikawa; Hitoshi Katai; Toshiro Nishida
Journal:  World J Surg Oncol       Date:  2020-07-23       Impact factor: 2.754

5.  Surgical treatment of gastric gastrointestinal stromal tumor.

Authors:  Seong-Ho Kong; Han-Kwang Yang
Journal:  J Gastric Cancer       Date:  2013-03-31       Impact factor: 3.720

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.